No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 3.6x · 10Y median 2.0x · 70th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 17
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T17:52:20.628Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Spectral AI, Inc. (MDAI) stock was $1.70 as of Oct 6, 2026, 1:50 PM EDT, up 0.59% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -24.1% · 3-year avg -19.4%/yr · 5-year avg -29.6%/yr
Spectral AI, Inc., an artificial intelligence (AI) company, focuses on predictive medical diagnostics in the United States. The company offers DeepView System, which uses proprietary AI algorithms to distinguish between fully damaged, partially damaged, and healthy human tissue characteristics invisible to the naked eye at the initial time point of wound presentation; and delivers a binary prediction on the wounds capacity to heal or not heal by a specified time point in the future to assist the physician in making a more accurate, timely, and informed decision regarding the treatment of the patient’s wounds.
Medical - Specialties · Dallas, TX
Next Earnings Date
Nov 10, 2026
35 days away
EPS Estimate
-0.14
Revenue Est.
$5.33M
Last Quarter Results
EPS
$-0.13
vs Estimate
$-0.14
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1MDAI | $54.10M | $1.70 | +0.59% | -24.11% | -29.57% | N/A | N/A |
| 2IMA | $53.63M | $4.75 | +1.17% | -45.19% | -50.73% | N/A | vs MDAI |
| 3BTMD | $53.37M | $1.21 | +8.04% | -62.24% | -35.12% | N/A | vs MDAI |
| 4ALDX | $53.11M | $0.88 | -4.68% | -83.77% | -36.54% | -18.91% | vs MDAI |
| 5NMAD | $52.53M | $4.25 | +5.85% | N/A | N/A | N/A | vs MDAI |
| 6RANI | $52.38M | $0.80 | +3.48% | +53.13% | -46.70% | N/A | vs MDAI |
forward FY estimate
N/A
$3.52M
vs Estimate
$4.17M
Consensus Rating
Based on 3 analysts
Average Price Target
$5.11
+200.8% upside
Low
$4.00
Current
$1.70
High
$6.25
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.14 | $-0.14 | $-0.12 | 2 |
| Quarter ending Dec 2026 | $-0.14 | $-0.13 | $-0.12 | 2 |
| Quarter ending Mar 2027 | $-0.24 | $-0.22 | $-0.21 | 1 |
| Quarter ending Jun 2027 | $-0.25 | $-0.23 | $-0.22 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.48 | $-0.47 | $-0.44 | 2 |
| FY 2027 | $-0.38 | $-0.31 | $-0.24 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $4.93M | $5.33M | $5.71M | 2 |
| Quarter ending Dec 2026 | $5.43M | $5.70M | $5.96M | 2 |
| Quarter ending Mar 2027 | $643476.00 | $675000.00 | $705931.00 | 1 |
| Quarter ending Jun 2027 | $672075.00 | $705000.00 | $737306.00 | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $18.39M | $18.53M | $18.66M | 2 |
| FY 2027 | $24.12M | $32.42M | $40.72M | 2 |
